Teriflunomide  	Teriflunomide  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
multiple  	multiple  	 JJ	O
sclerosis  	sclerosis  	 JJ	B-NP
Teriflunomide  	Teriflunomide  	 NNP	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
new  	new  	 JJ	O
active  	active  	 JJ	O
drug  	drug  	 NN	O
which  	which  	 WDT	O
has  	has  	 VBZ	O
recently  	recently  	 RB	O
been  	been  	 VBN	O
approved  	approved  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
first-line  	first-line  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
relapsing  	relapsing  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
MS  	MS  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
US 	US 	 NNP	O
,  	,  	 ,	O
Australia 	Australia 	 NNP	B-NP
,  	,  	 ,	O
Argentina 	Argentina 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
European  	European  	 NNP	O
Union 	Union 	 NNP	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
once-daily  	once-daily  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
application  	application  	 NN	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
well-established  	well-established  	 JJ	O
long-term  	long-term  	 JJ	O
safety  	safety  	 NN	O
profile 	profile 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
effect  	effect  	 NN	I-NP
is  	is  	 VBZ	O
considered  	considered  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
mediated  	mediated  	 VBN	O
via  	via  	 IN	O
the  	the  	 DT	O
inhibition  	inhibition  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
synthesis  	synthesis  	 FW	I-NP
of  	of  	 IN	I-NP
pyrimidine  	pyrimidine  	 NN	I-NP
in  	in  	 IN	O
proliferating  	proliferating  	 VBG	O
immune  	immune  	 JJ	O
cells 	cells 	 NNS	O
.  	.  	 .	O
Two  	Two  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
( 	( 	 -LRB-	O
TEMSO 	TEMSO 	 NNP	B-NP
,  	,  	 ,	O
TOWER 	TOWER 	 NNP	O
)  	)  	 -RRB-	O
tested  	tested  	 VBD	O
teriflunomide  	teriflunomide  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
relapsing  	relapsing  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
MS 	MS 	 NNP	B-NP
:  	:  	 :	O
efficacy  	efficacy  	 NNS	O
was  	was  	 VBD	O
shown 	shown 	 VBN	O
,  	,  	 ,	O
with  	with  	 IN	O
positive  	positive  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
on  	on  	 IN	O
relapse  	relapse  	 JJ	O
rates  	rates  	 NNS	O
and  	and  	 CC	O
disease  	disease  	 NN	B-NP
progression  	progression  	 NN	I-NP
for  	for  	 IN	O
14  	14  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
day 	day 	 NN	I-NP
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
in  	in  	 IN	O
these  	these  	 DT	O
studies  	studies  	 NNS	O
was  	was  	 VBD	O
favorable 	favorable 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
teriflunomide 	teriflunomide 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
regular  	regular  	 JJ	B-NP
monitoring  	monitoring  	 NN	I-NP
of  	of  	 IN	O
blood  	blood  	 NN	O
cell  	cell  	 NN	O
counts  	counts  	 NNS	O
and  	and  	 CC	O
liver  	liver  	 JJ	O
enzymes  	enzymes  	 NN	O
is  	is  	 VBZ	O
required 	required 	 VBN	O
.  	.  	 .	O
Teriflunomide  	Teriflunomide  	 NNP	B-NP
must  	must  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
used  	used  	 VBN	O
during  	during  	 IN	O
pregnancy 	pregnancy 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
article 	article 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
review  	review  	 VBP	O
recent  	recent  	 JJ	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
and  	and  	 CC	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
data 	data 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
potential  	potential  	 NN	O
of  	of  	 IN	O
teriflunomide  	teriflunomide  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
relapsing  	relapsing  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
MS 	MS 	 NNP	B-NP
.  	.  	 .	O
